Karyopharm stock price target lowered to $12 at Piper Sandler on restructuring
NegativeFinancial Markets

Karyopharm's stock price target has been lowered to $12 by Piper Sandler due to ongoing restructuring efforts. This adjustment reflects concerns about the company's financial stability and future growth potential, which could impact investor confidence and market performance. It's crucial for stakeholders to monitor these developments closely as they may influence Karyopharm's strategic direction and overall market position.
— Curated by the World Pulse Now AI Editorial System